| Sep 6 |
NIO To Rally Around 65%? Here Are 10 Top Analyst Forecasts For Friday
|
| Sep 6 |
Travere gains on full FDA approval for kidney drug Filspari
|
| Sep 5 |
Travere Therapeutics Announces Full FDA Approval of FILSPARI® (sparsentan), the Only Non-Immunosuppressive Treatment that Significantly Slows Kidney Function Decline in IgA Nephropathy
|
| Sep 4 |
High Growth Tech Stocks To Watch In September 2024
|
| Aug 30 |
Travere Therapeutics: Judgement Day Is Nigh For Sparsentan
|
| Aug 22 |
Travere Therapeutics to Present Abstracts at the Society for the Study of Inborn Errors of Metabolism Annual Symposium 2024
|
| Aug 4 |
Travere Therapeutics Second Quarter 2024 Earnings: Revenues Beat Expectations, EPS Lags
|
| Aug 3 |
Travere Therapeutics, Inc. (TVTX) Q2 2024 Earnings Call Transcript
|
| Aug 1 |
Travere Therapeutics files for mixed shelf offering
|
| Aug 1 |
Travere Therapeutics Non-GAAP EPS of -$0.65 beats by $0.07, revenue of $54.12M beats by $1.43M
|
